Intracranial Gadolinium Deposition-From the Journals
- Gadolinium-based contrast agents (GBCAs) represent a family of aminopolycarboxylic acid ligands chelated to gadolinium, a rare earth metal capable of altering the relaxivity of nearby water molecules by means of interaction with its unpaired electrons.
- As free gadolinium is cytotoxic, the presence of the organic ligand serves as a physiologic chaperone, allowing an otherwise toxic metal to be safely administered intravenously and excreted.
- Despite relatively uncomplicated initial clinical trials in the early 1990s, a 2006 study causally associated the administration of gadolinium with the development of nephrogenic systemic fibrosis in patients with pre-existing renal dysfunction.
- An article published in Radiology in 2015 showed Elemental gadolinium accumulates in neuronal tissues after intravenous administration of gadolinium-based contrast agents (GBCAs), even in patients with normal renal and hepatobiliary function.
- The clinical significance of these findings is incompletely understood at this time.
Radiology 2015 275:3, 772-782
Intracranial Gadolinium Deposition-From the Journals Reviewed by Sumer Sethi on Thursday, April 07, 2016 Rating: